Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer.

Genes - 16 Sept 2023

Aktar Sharmin, Islam Farhadul, Cheng Tracie, Gamage Sujani Madhurika Kodagoda, Choudhury Indra Neil, Islam Md Sajedul, Lu Cu Tai, Hamid Faysal Bin, Ishida Hirotaka, Abe Ichiro, Xie Nan, Gopalan Vinod, Lam Alfred K

Abstract excerpt

Combination strategies of KRAS inhibition with immunotherapy in treating advanced or recurrent colorectal carcinoma (CRC) may need to be assessed in circulating tumour cells (CTCs) to achieve better clinical outcomes. This study aimed to investigate the genomic variations of KRAS in CTCs and matched CRC tissues and compared mRNA expression of KRAS and CTLA-4 between wild-type and KRAS-mutated CTCs and CRC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Neoplasm Recurrence, Local

Share to Neoplastic Cells, Circulating

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA, Messenger

Source

Open in PubMed Open full text

Identifiers

PMID: 37761948
DOI: 10.3390/genes14091808
PMCID: PMC10530465

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer.PMID 37761948Read ↗

KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.Semantic proximity Read ↗

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Semantic proximity Read ↗

Comparison of KRAS gene in circulating tumor DNA levels vs histological grading of colorectal cancer patients through liquid biopsy.Semantic proximity Read ↗

Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis.Semantic proximity Read ↗

Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis.Semantic proximity Read ↗

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.Semantic proximity Read ↗

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.Semantic proximity Read ↗

KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.Semantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.